-transparent.png){kind=logo}
Gold therapy for 6 months was shown to be efficacious in reducing the severity of articular manifestations in 32 (63%) of 51 juvenile rheumatoid arthritis patients reviewed retrospectively. Similarly, reductions in the total number of involved joints were seen in 25 (49%) patients. Patients in whom a favorable response to therapy was noted had more severe joint involvement at the start of therapy than did nonresponders. In general, patients who responded experienced considerable improvement. Duration of disease prior to gold therapy initiation and disease onset type were not related to the probability of favorable response. Incidence of adverse side effects was low. Gold has recently been approved by the Food and Drug Administration for use in children.
E J Brewer, and
E H Giannini, and
E Barkley
May 1976,
Arizona medicine,
E J Brewer, and
E H Giannini, and
E Barkley
January 1974,
Medicinski arhiv,
E J Brewer, and
E H Giannini, and
E Barkley
April 1983,
Minerva pediatrica,
E J Brewer, and
E H Giannini, and
E Barkley
January 1964,
Annales paediatriae Fenniae,
E J Brewer, and
E H Giannini, and
E Barkley
December 1978,
The Journal of pediatrics,
E J Brewer, and
E H Giannini, and
E Barkley
December 1975,
Kinderarztliche Praxis,
E J Brewer, and
E H Giannini, and
E Barkley
August 1977,
Kinderarztliche Praxis,
E J Brewer, and
E H Giannini, and
E Barkley
January 1979,
American journal of diseases of children (1960),
E J Brewer, and
E H Giannini, and
E Barkley
September 1970,
The Journal of pediatrics,
E J Brewer, and
E H Giannini, and
E Barkley
February 1981,
Comprehensive therapy,
